Background: The incidence of asymptomatic pericardial effusion is high after cardiac surgery. Objective: To assess whether colchicine is effective in reducing post operative pericardial effusion volume. Design: Multicenter, randomized, double-blind, placebo-controlled study. Intervention : colchicine 1mg vs placebo, once daily for 14 days Setting :10 post operative cardiac rehabilitation centers. Patients: 200 patients at high risk of tamponade because of moderate to large persistent pericardial effusion (grade 2, 3 or 4 on a scale of 0 to 4 measured by echocardiography) more than 7 days after cardiac surgery. Measurements: The main end point will be change in effusion grade after 14 days of treatment. Secondary endpoints include frequency of late cardiac tamponade.
Clinically insignificant pericardial effusion is common after heart surgery with an incidence of 50 % to 85 % a few days after surgery Cardiac tamponade occurs in about 1-2 % of patients who undergo cardiac surgery and may develop slowly without clear-cut clinical signs. Most tamponade occurs more than 7 days after surgery which is a concern because, at that time, patients often have already been discharged from the hospital. No study has ever shown the efficacy any drug for this condition.In particular, we published a study demonstrating the absence of efficacy of a non steroidal anti inflammatory drug (Meurin P, Tabet JY, Thabut G, et al.French Society of Cardiology. Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind trial. Ann Intern Med. 2010 Feb2;152(3):137-43) Cochicine is widely used to treat inflammatory pericarditis ; is it efficient to treat post operative pericardial effusions ? this is the question we want to answer to. Design: Multicenter, randomized, double-blind, placebo-controlled study. Intervention : colchicine 1mg vs placebo, once daily for 14 days Setting :10 post operative cardiac rehabilitation centers. Patients: 200 patients at high risk of tamponade because of moderate to large persistent pericardial effusion (grade 2, 3 or 4 on a scale of 0 to 4 measured by echocardiography) more than 7 days after cardiac surgery. Measurements: The main end point will be change in effusion grade after 14 days of treatment. Secondary endpoints include frequency of late cardiac tamponade.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
199
oral form, 1 mg, once a day during 14 days
oral form, placebo
Bois Gibert
Ballan-Miré, France
Centre Médical de Bligny
Briis-sous-Forges, France
Clinique de Châtillon
Châtillon, France
Centre Dieulefit Santé
Dieulefit, France
Hopital Corentin Celton
Issy-les-Moulineaux, France
Clinique de la mitterie
Lomme, France
Centre Hospitalier Loire Vendée Océan
Machecoul, France
Clinique Iris
Marcy-l'Étoile, France
Maison du mineur
Vence, France
Clinique les Grands Près
Villeneuve-Saint-Denis, France
change in effusion grade
Time frame: 14 days
frequency of late cardiac tamponade
Time frame: 14 days
number of patients with at least a one-grade decrease in the effusion
Time frame: 14 days
mean change in the width of the effusion measured in millimeters
Time frame: 14 days
evolution of prespecified subgroups
* patients with inflammatory syndrom : crp \> 30 mg/l * patients receiving an anticoagulant * patients with a post pericardiotomy syndrom
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.